Damora Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Damora Therapeutics R&D Spending Growth & History (DMRA)
Damora Therapeutics's r&d spending was $26.9M for fiscal 2025.
View full Damora Therapeutics company overviewDamora Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $26.9M | $20.5M | +320.08% |
| 2024 | 2024-12-31 | $6.4M | −$17.4M | −73.08% |
| 2023 | 2023-12-31 | $23.8M | −$24.4M | −50.69% |
| 2022 | 2022-12-31 | $48.2M | $9.7M | +25.25% |
| 2021 | 2021-12-31 | $38.5M | $13.9M | +56.28% |
| 2020 | 2020-12-31 | $24.6M | $4.9M | +24.77% |
| 2019 | 2019-12-31 | $19.7M | — | — |
Damora Therapeutics quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $25.5M | $24.1M | +1643.34% |
| Q1 2026 | 2026-03-31 | $23.8M | $23.1M | +3406.93% |
| Q4 2025 | 2025-12-31 | $23.3M | $22.3M | +2213.29% |
| Q3 2025 | 2025-09-30 | $1.4M | $323,000 | +29.55% |
| Q2 2025 | 2025-06-30 | $1.5M | −$369,000 | −20.12% |
| Q1 2025 | 2025-03-31 | $678,000 | −$1.8M | −72.47% |
| Q4 2024 | 2024-12-31 | $1.0M | −$1.8M | −63.58% |
| Q3 2024 | 2024-09-30 | $1.1M | −$1.5M | −57.15% |
| Q2 2024 | 2024-06-30 | $1.8M | −$6.3M | −77.33% |
| Q1 2024 | 2024-03-31 | $2.5M | −$7.9M | −76.23% |
| Q4 2023 | 2023-12-31 | $2.8M | −$8.0M | −74.30% |
| Q3 2023 | 2023-09-30 | $2.6M | −$7.9M | −75.69% |
| Q2 2023 | 2023-06-30 | $8.1M | −$5.6M | −40.99% |
| Q1 2023 | 2023-03-31 | $10.4M | −$2.9M | −21.71% |
| Q4 2022 | 2022-12-31 | $10.8M | $655,000 | +6.48% |
| Q3 2022 | 2022-09-30 | $10.5M | $746,000 | +7.65% |
| Q2 2022 | 2022-06-30 | $13.7M | $5.1M | +58.74% |
| Q1 2022 | 2022-03-31 | $13.2M | $3.2M | +32.48% |
| Q4 2021 | 2021-12-31 | $10.1M | $2.4M | +30.45% |
| Q3 2021 | 2021-09-30 | $9.7M | $2.1M | +27.41% |
| Q2 2021 | 2021-06-30 | $8.6M | $4.1M | +91.25% |
| Q1 2021 | 2021-03-31 | $10.0M | $5.3M | +112.24% |
| Q4 2020 | 2020-12-31 | $7.8M | — | — |
| Q3 2020 | 2020-09-30 | $7.7M | $4.0M | +108.25% |
| Q2 2020 | 2020-06-30 | $4.5M | — | — |
| Q1 2020 | 2020-03-31 | $4.7M | — | — |
| Q3 2019 | 2019-09-30 | $3.7M | — | — |
Damora Therapeutics r&d spending trends
Over the last five fiscal years, Damora Therapeutics's r&d spending increased from $24.6M to $26.9M, a change of $2.3M. The latest reported quarter, Q2 2026, shows $25.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Damora Therapeutics source filings ↗